An observational study in Dilated Cardiomyopathy (DCM), sponsored by Wuhan Union Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Wuhan Union Hospital, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cardiomyopathy, Dilated with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Cardiomyopathy, Dilated · China.
Among the 23 studies in Cardiomyopathy, Dilated with a site in China, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 14th registered.
256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.
Browse Cardiomyopathy, Dilated studies →13 of the 23 studies in Cardiomyopathy, Dilated with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 250 across 97 observational studies indexed under Cardiomyopathy, Dilated.
Median enrollment 43 across the 12 interventional studies, 2,000 across the 11 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
Wuhan Union Hospital, China is the lead sponsor of 229 studies on the registry; 103 are open to participants now.
Wuhan Union Hospital, China has 3 studies filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
5 of the studies in Cardiomyopathy, Dilated with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354646Chinese Academy of Medical Sciences, Fuwai HospitalThe Application of T1 Mapping in Real-World | 2026-12-01 |
| NCT06922851Wuhan Union Hospital, ChinaProtein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM) | 2026-12-31 |
| NCT06794710RenJi HospitalEarly Identification and Treatment of Rare Cardiomyopathy Cohorts | 2027-05-30 |
| NCT07646600AstraZenecaObservational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults | 2027-08-31 |
| NCT07293338Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPrognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Cardiomyopathy, Dilated with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background of the study The etiology of dilated cardiomyopathy (DCM) is complex and involves a variety of genetic, environmental, and immunologic factors. Autoimmune reactions (especially anti-cardiac autoantibodies) play an important role in the development of DCM. In recent years, several clinical studies have suggested that anti-β1AR and anti-L-CaC antibodies are associated with cardiovascular death, ventricular tachycardia, and sudden death in patients with DCM, which is of great value in the prognostic evaluation of DCM. However, most of these studies are single-center studies with small sample sizes and non-uniform testing methods. In this study, we will use a multicenter, prospective cohort study to follow up DCM patients in China for a period of 3 years, to further accurately assess the clinical predictive value of anti-β1AR antibody and anti-L-CaC antibody on the prognosis of DCM patients, and to provide epidemiological information as well as targeted therapeutic targets for DCM.
Aims of the study A multicenter, prospective cohort study of anti-β1AR and anti-L-CaC antibodies for prognostic assessment of DCM patients, enrolling 1,000 DCM patients, to further accurately assess the prognostic value of the anti-AHA assay for DCM patients, and to provide targets for targeted treatment of DCM.
Dilated cardiomyopathy (DCM) is a heterogeneous cardiomyopathy characterized by ventricular enlargement and reduced myocardial contractile function, with the exception of hypertension, heart valve disease, congenital heart disease, or ischemic heart disease at the onset. The clinical manifestations of dilated cardiomyopathy include progressive cardiac enlargement, reduced ventricular systolic function, heart failure, ventricular or supraventricular arrhythmias, conduction system abnormalities, thromboembolism, and sudden death.The etiology of DCM is complex and involves a variety of factors, including genetics, environment, and immunity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite Endpoint of All-Cause Death, Heart Transplantation, and Rehospitalization for Heart Failure
Time frame: End of months 1, 6, 12, 18, 24 and 36
All-cause death, heart transplant, heart failure rehospitalization, or sudden death
Time frame: End of months 1, 6, 12, 18, 24 and 36
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 51 observational studies under Cardiomyopathy, Dilated, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 101. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.